Phase II randomized trial of MEK inhibitor pimasertib or placebo combined with gemcitabine in the first-line treatment of metastatic pancreatic cancer.

Results

Title:	Phase II randomized trial of MEK inhibitor pimasertib or placebo combined with gemcitabine in the first-line treatment of metastatic pancreatic cancer.
Authors:	Van, Cutsem Eric; Hidalgo, Manuel; Bazin, Igor; Canon, Jean-Luc; Poddubskaya, Elena; Manojlović, Nebojša S ; Milella, Michele; Radenkovic, Dejan V; Verslype, Chris; Guo, Wei; Damstrup, Lars; Hammel, Pascal;
Issue Date:	2015
Publication:	JOURNAL OF CLINICAL ONCOLOGY
ISSN:	0732-183X e1527-7755 Journal of Clinical Oncology Search Idenfier
Publisher:	American Society of Clinical Oncology
Type:	Conference Paper
Collation:	vol. 33 br. 3, Suppl. S (Meeting Abstract 344)
DOI:	10.1200/jco.2015.33.3_suppl.344
WoS-ID:	000356883800342
URI:	https://enauka.gov.rs/handle/123456789/812362
URL:	https://ascopubs.org/doi/10.1200/jco.2015.33.3_suppl.344
Metadata source:	(Preuzeto iz Nasi u WoS)
Note:	Gastrointestinal Cancers Symposium, San Francisco, CA JAN 15-17, 2015
M-category:	Mp. category will be shown later

13
OpenCitations

12
WEB OF SCIENCE^TM

Altmetric

Dimensions

Unpaywall

Google Scholar^TM